Charu Aggarwal, MD, MPH | Authors

Patient Profile 2: EGFR Exon 19 Deletion–Positive NSCLC

May 20, 2022

Shared insight on the diagnosis and management of EGFR exon 19 deletion–positive NSCLC, with regard for the potential of osimertinib in this setting.

NSCLC: Selecting Therapy Based on PD-L1 Status and Staging

May 20, 2022

A brief review of how treatment may be selected for a patient with NSCLC based on their PD-L1 expression and disease staging.

IMpower010 and KEYNOTE-091: Adjuvant Immunotherapy in NSCLC

May 13, 2022

Expert perspectives on the IMpower010 and KEYNOTE-091 trials, which assessed adjuvant immunotherapy in non–small cell lung cancer.

CheckMate-816: Neoadjuvant Chemoimmunotherapy for NSCLC

May 13, 2022

Shared insight on the CheckMate-816 trial and how immunotherapy may have a role in the neoadjuvant setting of non–small cell lung cancer.

Role of Immunotherapy in Newly Diagnosed NSCLC

May 06, 2022

A broad discussion on the role of immunotherapy in newly diagnosed NSCLC in both the neoadjuvant and adjuvant settings.

Patient Profile 1: Stage IIB NSCLC With High PD-L1 Expression

May 06, 2022

Shared insight on a patient profile of newly diagnosed non–small cell lung cancer with high PD-L1 expression and no driver mutation.

Factors in Selecting Therapy for Non-Small Cell Lung Cancer

April 29, 2022

Expert panelists look at all factors that inform treatment selection when managing a patient diagnosed with non–small cell lung cancer.

Biomarker Testing Practices in Non-Small Cell Lung Cancer

April 29, 2022

Comprehensive discussion on how biomarker testing and multidisciplinary care can improve the management of non–small cell lung cancer.

Modern Treatment Standards Require State-of-the-Art Molecular Profiling

October 15, 2021

“In my mind, the question is not who should get chemotherapy, but who can avoid chemotherapy in this day and age.”